

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,622
				Filing Date	March 18, 2004
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	1	of	16	Attorney Docket Number	05569.0004.DVUS11

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code ² (if known)			
	A1	5,258,289	11/02/1993	Davis, et al.	
	A2	5,534,617	07/09/1996	Cunningham, et al.	
	A3	5,567,610	10/22/1996	Borrebaeck, et al.	
	A4	5,580,717	12/03/1996	Dower, et al.	
	A5	5,698,426	12/16/1997	Huse	
	A6	5,780,225	07/14/1998	Wigler, et al.	
	A7	5,814,476	09/29/1998	Kauffman, et al.	
	A8	5,837,242	11/17/1998	Holliger, et al.	
	A9	5,837,500	11/17/1998	Ladner, et al.	
	A10	5,840,479	11/24/1998	Little, et al.	
	A11	5,855,885	01/05/1999	Smith, et al.	
	A12	5,858,657	01/12/1999	Winter, et al.	
	A13	5,871,907	02/16/1999	Winter, et al.	
	A14	5,935,823	08/10/1999	Fowlkes, et al.	
	A15	5,948,635	09/07/1999	Kay, et al.	
	A16	5,955,358	09/21/1999	Huse	
	A17	6,225,447	05/01/2001	Winter, et al.	
	A18	6,291,650	09/18/2001	Winter, et al.	
	A19	7,063,943	06/20/2006	McCafferty, et al.	
	A20	7,195,866	03/27/2007	Griffiths, et al.	

U.S. PUBLICATION DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code ² (if known)			

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds codes of USPTO Patent Documents as www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,622
				Filing Date	March 18, 2004
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	2	of	16	Attorney Docket Number	05569.0004.DVUS11

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	B1	EP 436597 B1	04/02/1997	Protein Engineering Corporation		
	B2	GB 91/25579.4	02/12/1991	Cambridge Antibody Technology Ltd.		
	B3	GB 91/25582.8	02/12/1991	Cambridge Antibody Technology Ltd.		
	B4	WO 92-01047	01/23/1992	Cambridge Antibody Technology Ltd.		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
	C1	U.S. Appl. No. 08/484,893 Advisory Action dated November 3, 1997	
	C2	U.S. Appl. No. 08/484,893 Final office action dated March 28, 1997	
	C3	U.S. Appl. No. 08/484,893 Non-final office action dated July 20, 1999	
	C4	U.S. Appl. No. 08/484,893 Non-Final office action dated June 17, 1996	
	C5	U.S. Appl. No. 08/484,893 Non-final office action dated June 9, 1998	
	C6	U.S. Appl. No. 08/484,893 Notice of Allowance dated March 29, 2000	
	C7	U.S. Appl. No. 08/484,893 Restriction Requirement dated December 7, 1998	
	C8	U.S. Appl. No. 09/196,522 Examiner's Amendment dated January 28, 2004	
	C9	U.S. Appl. No. 09/196,522 Restriction Requirement dated November 27, 1999	
	C10	U.S. Appl. No. 09/196,522 Non-final office action dated April 20, 2000	
	C11	U.S. Appl. No. 09/196,522 Non-final office action dated January 3, 2001	
	C12	U.S. Appl. No. 09/196,522 Notice of Allowance dated May 3, 2004	
	C13	U.S. Appl. No. 09/196,586 Advisory Action dated December 5, 2008	
	C14	U.S. Appl. No. 09/196,586 Advisory Action dated May 4, 2007	
	C15	U.S. Appl. No. 09/196,586 Final office action dated September 22, 2006	
	C16	U.S. Appl. No. 09/196,586 Final office action dated April 17, 2001	
	C17	U.S. Appl. No. 09/196,586 Final office action dated December 22, 2004	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,622
				Filing Date	March 18, 2004
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	3	of	16	Attorney Docket Number	05569.0004.DVUS11

	C18	U.S. Appl. No. 09/196,586 Final office action dated September 15, 2008	
	C19	U.S. Appl. No. 09/196,586 Non final office action dated April 10, 2000	
	C20	U.S. Appl. No. 09/196,586 Non-final office action dated April 4, 2002	
	C21	U.S. Appl. No. 09/196,586 Non-final office action dated December 28, 2005	
	C22	U.S. Appl. No. 09/196,586 Non-Final office action dated January 9, 2008	
	C23	U.S. Appl. No. 09/196,586 Non-final office action dated May 19, 2004	
	C24	U.S. Appl. No. 09/196,586 Restriction Requirement dated December 21, 1999	
	C25	U.S. Appl. No. 09/196,673 Advisory Action dated November 6, 2002	
	C26	U.S. Appl. No. 09/196,673 Advisory Action dated March 24, 2003	
	C27	U.S. Appl. No. 09/196,673 Final office action dated December 22, 2004	
	C28	U.S. Appl. No. 09/196,673 Final office action dated May 14, 2002	
	C29	U.S. Appl. No. 09/196,673 Non-final office action dated April 11, 2000	
	C30	U.S. Appl. No. 09/196,673 Non-final office action dated January 18, 2001	
	C31	U.S. Appl. No. 09/196,673 Non-final office action dated March 4, 2004	
	C32	U.S. Appl. No. 09/196,673 Notice of Allowance dated November 3, 2005	
	C33	U.S. Appl. No. 09/196,673 Restriction Requirement dated December 21, 1999	
	C34	U.S. Appl. No. 09/309,639 Non-final office action dated January 3, 2001	
	C35	U.S. Appl. No. 09/309,639 Official communication dated August 22, 2003	
	C36	U.S. Appl. No. 09/309,639 Restriction Requirement dated September 1, 2000	
	C37	U.S. Appl. No. 09/416,902 Advisory Action dated September 6, 2006	
	C38	U.S. Appl. No. 09/416,902 Final office action dated March 10, 2006	
	C39	U.S. Appl. No. 09/416,902 Non-final office action dated July 28, 2005	
	C40	U.S. Appl. No. 09/416,902 Non-final office action dated August 16, 2007	
	C41	U.S. Appl. No. 09/416,902 Non-final office action dated February 3, 2009	
	C42	U.S. Appl. No. 09/416,902 Non-final office action dated September 19, 2008	
	C43	U.S. Appl. No. 09/416,902 Notice of Allowance dated February 4, 2008	
	C44	U.S. Appl. No. 09/416,902 Restriction Requirement dated September 18, 2000	
	C45	U.S. Appl. No. 09/417,478 Advisory Action dated January 29, 2007	
	C46	U.S. Appl. No. 09/417,478 Final office action dated April 1, 2009	
	C47	U.S. Appl. No. 09/417,478 Final office action dated December 14, 2007	
	C48	U.S. Appl. No. 09/417,478 Final office action dated July 5, 2006	
	C49	U.S. Appl. No. 09/417,478 Non-final office action dated January 20, 2000	
	C50	U.S. Appl. No. 09/417,478 Non-final office action dated June 12, 2008	
	C51	U.S. Appl. No. 09/417,478 Non-final office action dated May 17, 2007	
	C52	U.S. Appl. No. 09/417,478 Non-final office action dated November 20, 2000	
	C53	U.S. Appl. No. 09/417,479 Non-final office action dated May 3, 2006	
	C54	U.S. Appl. No. 09/417,479 Restriction Requirement dated June 26, 2000	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,622
				Filing Date	March 18, 2004
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	4	of	16	Attorney Docket Number	05569.0004.DVUS11

	C55	U.S. Appl. No. 09/706,507 Non-final office action dated May 5, 2006	
	C56	U.S. Appl. No. 09/706,507 Restriction Requirement dated May 21, 2001	
	C57	U.S. Appl. No. 09/726,219 Non-final office action dated August 12, 2003	
	C58	U.S. Appl. No. 09/726,219 Notice of Allowance dated February 25, 2004	
	C59	U.S. Appl. No. 09/726,219 Restriction Requirement dated March 12, 2003	
	C60	U.S. Appl. No. 07/971,857 Advisory Action dated August 15, 1996	
	C61	U.S. Appl. No. 07/971,857 Examiner's Interview Summary Record dated December 13, 1996	
	C62	U.S. Appl. No. 07/971,857 Examiner's Interview summary Record dated April 24, 1997	
	C63	U.S. Appl. No. 07/971,857 Final office action dated April 23, 1996	
	C64	U.S. Appl. No. 07/971,857 Non-final office action dated June 30, 1995	
	C65	U.S. Appl. No. 07/971,857 Notice of Allowance dated July 23, 1997	
	C66	U.S. Appl. No. 07/971,857 Response to 312 Amendment dated April 20, 1999	
	C67	U.S. Appl. No. 10/803,653 Advisory Action dated October 11, 2007	
	C68	U.S. Appl. No. 10/803,653 Final office action dated May 8, 2007	
	C69	U.S. Appl. No. 10/803,653 Final office action dated November 5, 2008	
	C70	U.S. Appl. No. 10/803,653 Non-final office action dated January 18, 2008	
	C71	U.S. Appl. No. 10/803,653 Non-final office action dated October 4, 2006	
	C72	U.S. Appl. No. 10/803,653 Notice of Allowance dated May 21, 2009	
	C73	U.S. Appl. No. 11/555,464 Non-final office action dated March 5, 2009	
	C74	U.S. Appl. No. 11/555,519 Non-final office action dated March 5, 2009	
	C75	Abbas, et al. , "Cellular and Molecular Immunology," Saunders, Third Edition, p. 412 (1997)	
	C76	Alberts, et al. , "Molecular Biology of the Cell," Garland Publications, Third Edition, p. 96 (1994)	
	C77	Avrameas and Ternynck , "Natural Antibodies," in Delves, P., and I. Roitt, The Encyclopedia of Immunology, Second Edition, Academic Press, pp. 1806-1809 (1998)	
	C78	Barbas, et al. , "Assembly of Combinatorial Antibody Libraries on Phage Surfaces: The Gene III Site," Proc. Natl. Acad. Sci. (USA), Vol. 88, pp. 7978-7982 (1991)	
	C79	Barbas, et al. , "Combinatorial Immunoglobulin Libraries on the Surface of Phage (Phabs): Rapid Selection of Antigen Specific Fabs," Methods: Companion Methods Enzymol., Vol. 2, pp. 119 (1991)	
	C80	Beidler, et al. , "Cloning and High Level Expression of a Chimeric Antibody with Specificity for Human Carcinoembryonic Antigen," J. Immunology, Vol. 141, pp. 4053-4060 (1988)	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,622
				Filing Date	March 18, 2004
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	5	of	16	Attorney Docket Number	05569.0004.DVUS11

	C81	Berborowicz and Jaroszewski , "Carcinoembryonic Antigen as an Autoantigen," Immunol. Ser., Vol. 52, pp. 65-83 (1982)	
	C82	Berzofsky, et al. , "Antigen-Antibody Interactions and Monoclonal Antibodies," in Paul, W., Fundamental Immunology, Second Edition, Chapter 12, pp. 332 (see also, Fourth Edition, 1994 (1999) Chapter 4, p. 91)	
	C83	Beste, G., et al. , "Small Antibody-like Proteins with Prescribed Ligand Specificities Derived from the Lipocalin Fold," Sci. USA, Vol. 96, No. 5, pp. 1898-19903, ISSN 0027-8424 (1999) Abstract	
	C84	Boerner, et al. , "Production of Antigen-Specific Human Monoclonal Antibodies From in Vitro-Primed Human (Splenocytes)," J. Immunol. Vol. 147, pp. 86-95 (1991)	
	C85	Breitling, et al. , "A Surface Expression Vector for Antibody Screening," Gene, Vol. 104, pp. 147-153 (1991)	
	C86	Buck , Cell Biology, Vol. 3, pp. 179-188 (1992)	
	C87	Burton, et al. , "A Large Array of Human Monoclonal Antibodies to Type 1 Human Immunodeficiency Virus from Combinatorial Libraries of Asymptomatic Seropositive Individuals," Proc. Natl. Acad. Sci., Vol. 88, pp. 10134-10137 (1991)	
	C88	Casali and Notkins , "Probing the Human [B-cell] Repertoire with EBV: Polyreactive Antibodies and CD5+ B Lymphocytes," Ann. Rev. Immunol., Vol. 7, pp. 513-535 (1989)	
	C89	Chang, et al. , "Expression of Antibody Fab Domains on Bacteriophage Surfaces: Potential Use of Antibody Selection," J. Immunol., Vol. 1047, pp. 3610-3614 (1991)	
	C90	Cohen, P. L. , "Systemic Autoimmunity," in Paul, W., Fundamental Immunology, Fourth Edition, Lippincott-Raven, p. 1608 (1997).	
	C91	Delves, P.J. , "Autoimmunity," in Delves, P. and I. Roitt, The Encyclopedia of Immunology, Second Edition, Academic Press, p. 292 (1998)	
	C92	Dighiero, et al. , "Naturally Occurring Autoantibodies Against Nine Common Antigens in Human Sera," J. Immunol., Vol. 218, No. 128, pp. 2788-2792 (1982)	
	C93	Fomsgaard, et al. , "Auto-antibodies to Tumor Necrosis Factor in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections," Scand. J. Immunol., Vol. 30, pp. 219-223 (1989)	
	C94	Golub, E. , "The Limits of Medicine: How Science Shapes our Hope for the Cure," Times Books/Random House, p. 117-120 (1994)	
	C95	Golub, E., and Green, D. , "Immunology: A Synthesis," Sinauer Associates, Second Edition, p. 531 (1991)	
	C96	Goodnow, et al. , "Altered Immunoglobulin Expression and Functional Silencing of Self-Reactive B Lymphocytes in Transgenic Mice," Nature, Vol. 334, pp. 676-682 (1988)	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,622
				Filing Date	March 18, 2004
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	6	of	16	Attorney Docket Number	05569.0004.DVUS11

	C97	Gram, et al. , "In vitro Selection and Affinity Maturation of Antibodies from a Naïve Combinatorial Immunoglobulin Library," Proc. Natl. Acad. Sci USA, Vol. 89, pp. 3576-3580 (1992)	
	C98	Griffiths, et al. , "Human Anti-Self Antibodies with High Specificity from Phage Display Libraries, EMBO J., Vol. 12, pp. 725-734 (1993)	
	C99	Griffiths, et al. , "Isolation of High Affinity Human Antibodies Directly from Large Synthetic Repertoires," EMBO J., Vol. 13, pp. 3245-3260 (1994)	
	C100	Guilbert, et al. , "Naturally Occurring Antibodies Against Nine Common Antigens in Human Sera," J. Immunol., Vol. 128, pp. 2779-2787 (1982)	
	C101	Hartley, O. , "The Use of Phage Display in the Study of Receptors and Their Ligands," J. of Receptors and Signal Transduction, Vol. 22, Nos. 1-4, pp. 373-393 (2002)	
	C102	Hartman and Wright , "Identification of Autoantibodies Specific for the Neutrophil Adhesion Glycoproteins CD11b/CD18 in Patients with Autoimmune Disease (Neutroenia," Blood, Vol. 78, pp. 1096-1104 (1991)	
	C103	Hirohata, et al. , "Frequency Analysis of Human Peripheral Blood B Cells Producing IGM-Rheumatoid Factor," J. Immunol., Vol. 145, pp. 1681-1686 (1990)	
	C104	Holness, et al. , Journal of Cell Science, Vol. 107, pp. 2065-2070 (1994)	
	C105	Hoogenboom, et al. , "Building Antibodies from their Genes," Rev. Fr. Transfus. Hemobiol., Vol. 36, pp. 19-47 (1993)	
	C106	Hoogenboom, et al. , "Multi-Subunit Proteins on the Surface of Filamentous Phage: Methodologies for Displaying Antibody (Fab) Heavy and Light Chains," Nucl. Acids Res., Vol. 19, pp. 4133-4137 (1991)	
	C107	Huse , "Combinatorial Antibody Expression Libraries in Filamentous Phage," Chapter 5 of Antibody Engineer, Borrebaeck (ed.), W.H. Freeman and Co. N.Y. (1992)	
	C108	International Search Report of European Patent Application No. 04005419.9 dated August 9, 2004	
	C109	Jacobsson, K., et al. , "Shot-gun Phage Display Mapping of Two Streptococcal Cell-Surface Proteins," Microbial Research, Vol. 152, No. 2, pp. 121-128, ISSN 0944-4013 (1997) Abstract	
	C110	Kaushik, et al. , "Comparative Analysis of Natural Antibody Specificities Among Hybridomas Originating from Spleen and Peritoneal Cavity of Adult NZB and BALB/c Mince," Scand. J. Immunol., Vol. 27, pp. 461-471 (1988)	
	C111	Klein and Horejsi , "Immunology" [Chapter 20, "immunological Tolerance"], Blackwell Scientific, Second Edition, p. 527 (1997)	
	C112	Koga, et al. , "Mouse-Human Chimeric Monoclonal Antibody to Carcinoembryonic Antigen (CEA): In Vitro and In Vivo Activities," Hybridoma, Vol. 9, pp. 43-56 (1990)	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,622
				Filing Date	March 18, 2004
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	7	of	16	Attorney Docket Number	05569.0004.DVUS11

	C113	Landsteiner, K. , "The Specificity of the Immune Response," quoted in Golub, E., Immunology: A Synthesis, Sinauer Associates, p. 19-25 [1991 book] (1987)	
	C114	Lehninger, et al. , Principles of Biochemistry, 2nd ed., Title Page, copy right page and p. G-4 only (1993)	
	C115	Lobel, L.I., et al. , "Filamentous Phage Displaying the Extracellular Domain of the hLH/CG Receptor Bind hCG Specifically," Endocrinology, Vol. 138, No. 3, pp. 1232-1239, ISSN: 0013-7227 (1997) Abstract	
	C116	Logtenberg, et al. , "Analysis of the Human Tonsil B Cell Repertoire by Somatic Hybridization: Occurrence of Both "Monospecific" and "Multispecific" (auto) Antibody-Secreting Cells," Eur. J. Immunol., Vol. 17, pp. 855-859 (1987)	
	C117	Lydyard, et al. , "The Antibody Repertoire of Early Human B Cells," Scand. J. Immunol., Vol. 31, pp. 33-43 (1990)	
	C118	Mamula, et al. , "The Specificity of Human Anti-Cyclochrome c Autoantibodies that Arise in Autoimmune Disease," J. Immunol., Vol. 144, pp. 1835-1840 (1990)	
	C119	Marks, et al. , "Molecular Evolution of Proteins on Filamentous Phage," J. Biol. Chem., Vol. 267, p. 16007-16010 (1992)	
	C120	McCafferty, J., et al. , "Phage-Enzymes: Expression and Affinity Chromatography of Functional Alkaline Phosphatase on the Surface of Bacteriophage," Protein Engineering, Vol. 4, No. 8, pp. 955-961 (1991)	
	C121	McHeyzer-Williams, et al. , "Clonal Analysis of Autoantibody-Producing Cell Precursors in the Preimmune B Cell Repertoire," J. Immunol., Vol. 141, pp. 4118-4123 (1988)	
	C122	Mullinax, et al. , "Identification of Human Antibody Fragment Clones Specific For Tetanus Toxoid in a Bacteriophage λ Immunoexpression Library," Proc. Natl. Acad. Sci., USA, Vol. 87, pp. 8095-8099 (1990)	
	C123	Nemazee and Burk , "Clonal Deletion of B Lymphocytes in a Transgenic Mouse Bearing Anti-MHC Class I Antibody Genes," Nature, Vol. 377, pp. 562-566 (1989)	
	C124	Neumaier, et al. , "Cloning of the Genes for T84.66, an Antibody that has a High Specificity and Affinity for Carcinoembryonic Antigen, and Expression of Chimeric Human/Mouse T84.66 Genes in Myeloma and Chinese Hamster Ovary Cells," Cancer Research, Vol. 50, pp. 2128-2134 (1990)	
	C125	Nossal, G.V.J. , "Cellular Mechanisms of Immune[ologic] Tolerance," Ann. Rev. Immunol., Vol. 1, pp. 33-62 (1983)	
	C126	Nossal, G.V.J. , "Molecular and Cellular Aspects of Immunologic Tolerance," Eur. J. Biochem., Vol. 202, pp. 729-737 (1991)	
	C127	Persson, et al. , "Generation of Diverse High-Affinity Human Monoclonal Antibodies by Repertoire Cloning," Proc. Natl. Acad. Sci., Vol. 88, pp. 2432-2436 (1991)	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,622
				Filing Date	March 18, 2004
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	8	of	16	Attorney Docket Number	05569.0004.DVUS11

	C128	Roitt, et al. , Immunology, Second Edition, 1989, Ivan Roitt, et al., Gower Publishing, New York, p. 51 (1989)	
	C129	Ruf., et al. , "Various Expressions of a Unique Anti-Human Thymoglobulin Antibody Repertoire in Normal State and Autoimmune Disease," Blood, Vol. 78, pp. 1096-1104 (1991)	
	C130	Smith, et al. , "Phage Display," Chem. Rev., Vol. 97, pp. 391-410 (1997)	
	C131	Svenson, et al. , "IgG Autoantibodies Against Interleukin 1 α in Sera of Normal Individuals," Scand. J. Immunol., Vol. 29,, pp. 489-492 (1989)	
	C132	Tomlinson, et al. , "The Repertoire of Human Germline Vh Segments (Sequences Reveals about Fifty Groups of VH Segments] with Different Hypervariable Loops," J. Mol. Biol., Vol. 227, pp. 776-798 (1992)	
	C133	Ura, et al. , "Studies on Circulating Antibody Against Carcinoembryonic Antigen (CEA) and CEA-like Antigen in Cancer Patients," Cancer Letters, Vol. 25, pp. 283-295 (1985)	
	C134	Waterhouse, et al. , "Combinatorial Infection and in Vivo Recombination: A Strategy for Making Large Phage Antibody Repertoires," Nucl. Acids Res., Vol. 21, pp. 2265-2266 (1993)	
	C135	Weidanz, J.A., et al. , "Display of Functional Alphabets Single-Chain T-Cell Receptor Molecules on the Surface of Bacteriophage," J. Immunol. Methods, Vol. 221, (1-2), pp. 59-76, ISSN 0022-1759 (1998) Abstract	
	C136	Wilson and Stanfield , "Antibody-Antigen Interactions: New Structures and New Conformational Changes," Curr. Opin. Structural Biol., Vol. 4, pp. 857-867 (1994)	
	C137	Winter, et al. , "Making Antibodies by Phage Display Technology," Annu. Rev. Immunol., Vol. 12, pp. 433-455 (1994)	
	C138	Promega Technical Bulletin, printed January 11, 2008, revised December 2006, pGEM-3ZF(+) Vector, 9 pages	
	C139	Promega Technical Bulletin, printed January 11, 2008, revised December 2006, pGEM-3ZF(-) Vector, 9 pages	
	C140	Stratagene Instruction Manual, printed January 11, 2008, revised 2003, pBluescript II Phagemic Vectors, 37 pages	
	C141	First Amended Complaint, Filed March 8, 2002 - Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (24 pages) (U.S. District Court, District of Columbia)(signed by John S. Skilton, Attorney for Plaintiff.)	
	C142	Cambridge Antibody Technology Limited's Answer to First Amended Complaint, Filed March 22, 2002 - Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia)(signed by Brian H. Corcoran, Attorney for Defendant).	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,622
				Filing Date	March 18, 2004
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	9	of	16	Attorney Docket Number	05569.0004.DVUS11

	C143	Il'ichev, A.A., et al., "M13 Filamentous Bacteriophage in Protein Engineering", Molekulyarnaya Biologiya, Vol. 24, No. 2, pp. 530-535, (March-April 1990).	
	C144	Iliychev, A.A., et al., "M13 Filamentous Bacteriophage for Protein Engineering", Molekulyarnaya Biologiya, Vol. 24, No. 2, pp. 530-535, (March-April 1990). (In Russian with Translated Abstract)	
	C145	Deposition Transcript of David W. Clough, taken April 19, 2002 (Morphosys AG v. Cambridge Antibody Technology Limited, U.S. District Court, Northern District of Illinois, Eastern Division).	
	C146	E.I. du Pont de Nemours v. Cetus Corp., 19 USPQ2d 1174, (DC N.Cal. 1990).	
	C147	OddzOn Products Inc. v. Just Toys Inc., 43 USPQ2d 1641(CAFC 1997).	
	C148	Deposition Transcript of George P. Smith, Ph.D., taken 14 May 2002, Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C149	Deposition Transcript of Dr. David Chiswell, taken 29 April 2002; Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C150	Deposition Transcript of Dr. Gregory Paul Winter, taken April 30, 2002; Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C151	Vol. I - Deposition Transcript of Sean Malcolm Walton, taken 01 May 2002, Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C152	Vol. II - Deposition Transcript of Sean Malcolm Walton, taken 02 May 2002, Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C153	Declaration of George P. Smith, Ph.D., Under 37 C.F.R. § 1.132, executed 30 June 1995 (submitted during the prosecution of U.S. Application No. 08/322,352).	
	C154	Declaration of Brian K. Kay, Ph.D., executed 28 June 1998, (submitted during the prosecution of European Appln. No. 91913039.3)	
	C155	Abstract of George P. Smith, Grant No. 1R01GM41478-01A1, Project Start Date: July 1, 1989, Dept. of Health & Human Services.	
	C156	Smith Grant Application, entitled: "Filamentous Phage Physiology", dated November 1, 1988	
	C157	Northern Telecom Inc. v. Datapoint Corp., 15 USPQ 1321., (CAFC 1990). Letter of Dr. Smith Re: NIH grant proposals, Dated June 27, 1997	
	C158	Letter of Dr. Smith Re: NIH grant proposals dated June 27, 1997	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,622
				Filing Date	March 18, 2004
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	10	of	16	Attorney Docket Number	05569.0004.DVUS11

	C159	Barbas and Lerner "Combinatorial Immunoglobulin Libraries on the surface of phage (Phabs): rapid selection of anti-specific fabs." Methods: a companion to methods in Enzymology Vol. 2 (2): 119-124 (1991).	
	C160	Interlocutory Decision in Opposition Proceedings to the European Patent EP-B-0589877 dated April 15, 2002 (reference number SMW/CP9503921)	
	C161	Notice of Appeal to the European Patent EP-B-0589877 from Dyax Corp., filed Jun. 17, 2002	
	C162	Communication from EPO on Notice of Appeal filed by Dyax, issued October 21, 2002	
	C163	Notice of Appeal to the European Patent EP-B-0589877 from BioInvent Therapeutic AB, filed June 14, 2002	
	C164	Appeal No. T0639/02-334 from BioInvent Therapeutic AB to the European Patent EP-B-0589877, filed August 22, 2002	
	C165	Notice of Appeal to the European Patent EP-B-0589877 from MorphoSys AG filed June 20 2002 and Grounds of the Appeal filed August 22, 2002	
	C166	Notice of Appeal filed June 24, 2002 and Grounds of Appeal filed August 22, 2002 from Cambridge Antibody Technology Limited against the Decision of the Opposition Division	
	C167	Notice of Opposition to the European Patent EP-B-0589877 from BioInvent International AB, filed October 24 2002	
	C168	Document D80 in Appeal No. T0639/02-334: HHS' Freedom of Information Act (FOIA) regulations: table of contents, 5.1, 5.2, 5.3, 5.5, 5.21, 5.22, 5.24, 5.31, 5.32, 5.33, 5.34, 5.35, 5.51, 5.61 and 5.65	
	C169	Document D81 in Appeal No. T0639/02-334: Smith Declaration	
	C170	Document D82 in Appeal No. T0639/02-334: Copy of Grant Application GM 41478 and renewal applications supplied by the DHH	
	C171	Document D83 in Appeal No. T0639/02-334: Letter dated 26 August 1999 from Cambridge Antibody Technology Ltd in opposition proceedings against EP 0 527 839	
	C172	Document D85 in Appeal No. T0639/02-334: Proprietor's letter of 12 November 1997 and amended claims	
	C173	Document D86 in Appeal No. T0639/02-334: EP 0774 511 A1	
	C174	Document D87 in Appeal No. T0639/02-334: Proprietor's letter of 15 November 2000	
	C175	Document D88 in Appeal No. T0639/02-334: Grounds of Appeal dated 22 August 2002 from present opponent in opposition proceedings against EP 0589 877	
	C176	Document D89 in Appeal No. T0639/02-334: OD's Written Interlocutory Decision in opposition proceedings against EP 0 589 877	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,622
				Filing Date	March 18, 2004
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	11	of	16	Attorney Docket Number	05569.0004.DVUS11

	C177	Document D90 in Appeal No. T0639/02-334: Marvin & Hohn (1969). Bacteriological Rev 33(2), 172-209	
	C178	Document D91 in Appeal No. T0639/02-334: Better et al. (1988). Science 240, 1041-1043	
	C179	Document D92 in Appeal No. T0639/02-334: Sambrook & Russell (2001). Molecular cloning: a laboratory manual 3rd Edition, Cold Spring Harbor Press; particular pages 18.115 to 18.122 "Filamentous phage display"	
	C180	Notice of Opposition to the European Patent EP-B-0589877 from Crucell Holland B.V, filed October 30, 2002	
	C181	Document D13: Communication of the European Office of 28 June 2001	
	C182	Document D17: Vieira and Messing (1987), Methods Enzymol. 153, 3-11	
	C183	Document D27: Details of Smith Grant application and second and third year renewals thereof as provided by the DHHS in response to a Freedom to Information Act (FOIA) request	
	C184	Notice of Opposition to the European Patent EP-B-0589877 from Dyax Corp.	
	C185	Document D1: EPO register print-out for the patent application with file history information	
	C186	Document D3: Claims filed with the divisional application	
	C187	Document D7: Pluckthun and Skerra, "Expression of functional antibody Fv and Fab fragments in Escherichia coli," Methods in Enzymology, Vol. 178 (1989), pages 497-515	
	C188	Document D8: Hoogenboom et al., "Multi-subunit proteins on the surface of filamentous phage: methodology for displaying antibody (Fab) heavy and light chains," Nucleic Acids Research, Vol 19, No. 15 (1991), pages 4133-4137.	
	C189	Notice of Opposition to the European Patent EP-B-0589877 from MorphoSys, filed October 30 2002	
	C190	Document D1: Genentech, US Patent Application 07/621,667, priority document to EP 92902109.5	
	C191	Opposition to European patent EP-B-0589877, cited opposition document D2: Nelson et al. "Filamentous phage DNA cloning vectors: a noninfective mutant with a nonpolar deletion in gene III", Virology 108: 338-350 (1981)	
	C192	Opposition to European patent EP-B-0589877, cited opposition document D3: McCoy and Khorana "Introduction and characterization of amber mutations in the bacteriorhodopsin gene", J. Bio. Chem. 258: 8456-8461 (1983)	
	C193	Opposition to European patent EP-B-0589877, cited opposition document D5: Bullock et al. "XL1-blue: a high efficiency plasmid transforming recA Escherichia coli strain with beta-galactosidase selection", Bio Techniques 5: 376-378 (1987)	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,622
				Filing Date	March 18, 2004
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	12	of	16	Attorney Docket Number	05569.0004.DVUS11

	C194	Opposition to European patent EP-B-0589877, cited opposition document D6: Schnee et al. "Construction and expression of a recombinant antibody-targeted plasminogen activator", Proc. Natl. Acad. Sci. USA 84:6904-6908 (1987)	
	C195	Opposition to European patent EP-B-0589877, cited opposition document D9: De La Cruz et al. "Immunogenicity and epitope mapping of foreign sequences via genetically engineered filamentous phage", J. Bio. Chem. 263: 4318-4322 (1988)	
	C196	Opposition to European patent EP-B-0589877, cited opposition document D15: Parmley and Smith "Filamentous fusion phage cloning vectors for the study of epitopes and design of vaccines", Adv. Exp. Med. Biol. 251: 215-218 (1989)	
	C197	Opposition to European patent EP-B-0589877, cited opposition document D18: Chaudhary et al. "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin", Nature 339: 394-397 (1989)	
	C198	Opposition to European patent EP-B-0589877, cited opposition document D23: US 517 659 "Affymax priority document", entitled "Recombinant Library Screening Methods", priority document filed 1 May 1990 for EP-A-0 527 839 (Article 54(3) EPC)	
	C199	Opposition to European patent EP-B-0589877, cited opposition document D26: Scott and Smith "Searching for peptide ligands with an epitope library", Science 249: 386-389 (1990)	
	C200	Opposition to European patent EP-B-0589877, cited opposition document D27: Devlin et al. "Random peptide libraries: a source of specific protein binding molecules", Science 249: 404-405 (1990)	
	C201	Opposition to European patent EP-B-0589877, cited opposition document D37: Markland et al. "Design, construction and function of a multicopy display vector using fusions to the major coat protein of bacteriophage M13", Gene 109: 13-19 (1991)	
	C202	Opposition to European patent EP-B-0589877, cited opposition document D38: Roberts et al. "Directed evolution of a protein: selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage", Proc. Natl. Acad. Sci. USA 89: 2429-2433 (1992)	
	C203	Opposition to European patent EP-B-0589877, cited opposition document D39: Glockshuber et al. "The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in Escherichia coli", Biochemistry 31: 1270-1279 (1992)	
	C204	Opposition to European patent EP-B-0589877, cited opposition document D41: Kay et al. "Phage display of peptides and proteins", A laboratory Manual (1996) (Cover page and Foreward enclosed)	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,622
				Filing Date	March 18, 2004
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	13	of	16	Attorney Docket Number	05569.0004.DVUS11

	C205	Opposition to European patent EP-B-0589877, cited opposition document D42: Proba et al. "A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding", J. Mol. Biol. 265: 161-172 (1997)	
	C206	Opposition to European patent EP-B-0589877, cited opposition document D43: Proba et al. "Antibody scFv fragments without disulfide bonds made by molecular evolution", J. Mol. Biol. 275: 245-253 (1998)	
	C207	Opposition to European patent EP-B-0589877, cited opposition document D44: Letter of 18 November 1992 to EPO from Kilburn Strode in prosecution of EP-B-0 349 578	
	C208	Opposition to European patent EP-B-0589877, cited opposition document D45: Page 3 of EPO letter of 19 October 1993 addressed to Plougmann, Ole (c/o Plougmann Vingtoft A/S) in prosecution of EP-B-0 768 377	
	C209	Opposition to European patent EP-B-0589877, cited opposition document D46: Letter of 22 September 1994 to EPO from Plougmann & Vingtoft in prosecution of EP-B-0 768 377	
	C210	Opposition to European patent EP-B-0589877, cited opposition document D47: Extract from OD Decision in opposition proceedings against EP-B-0 201 184, (1995)	
	C211	Opposition to European patent EP-B-0589877, cited opposition document D48: Letter of 14 February 1996 to EPO from Hepworth, Lawrence, Bryer & Bizley in prosecution of EP-A-0 527 839, 1996	
	C212	Opposition to European patent EP-B-0589877, cited opposition document D49: the Boards of Appeal of the European Patent Office decision of 8 May 1996, case number T694/92 – 3.3.4	
	C213	Opposition to European patent EP-B-0589877, cited opposition document D50: Extract from opposition proceeding against EP-B-0 349 578 (1996)	
	C214	Opposition to European patent EP-B-0589877, cited opposition document D51: Extract from OD Decision in proceedings against EP-B-0 349 578 (1998)	
	C215	Opposition to European patent EP-B-0589877, cited opposition document D53: Declaration of professor sir Aaron Klug, Ph.D. with exhibits, (23 June 1998)	
	C216	Opposition to European patent EP-B-0589877, cited opposition document D54: preprint of paper by Scott and Smith submitted to Science, date of availability to public unproven	
	C217	Opposition to European patent EP-B-0589877, cited opposition document D55: Smith grant application, date of availability to public unproven	
	C218	Opposition to European patent EP-B-0589877, late filed document D56: claim for infringement of 24 September 1998, from Cambridge Antibody Technology Limited to EPO	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,622
				Filing Date	March 18, 2004
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	14	of	16	Attorney Docket Number	05569.0004.DVUS11

	C219	Opposition to European patent EP-B-0589877, late filed document D58: McConnell et al. "Constrained peptide libraries as a tool for finding mimotopes", Gene 151: 115-118 (1994).	
	C220	Opposition to European patent EP-B-0589877, late filed document D59: two chapters of "Lambda II" (eds. Hendrix et al.) Cold Spring Harbour Laboratory, Cold Spring Harbour, New York, 1983: "A Beginner's Guide to Lambda Biology" (Arber) (pp. 381-395) and "Tail Assembly and Injection" (Katsura)(pp. 331-346).	
	C221	Opposition to European patent EP-B-0589877, late filed document D60: Parmley & Smith "Filamentous fusion phage cloning vectors for the study of epitopes and design vaccines", Adv. Exp. Med. Biol. 251: 251-8 (1989). The document was not admitted to the proceedings.	
	C222	Opposition to European patent EP-B-0589877, late filed document D63: Declaration of William D. Huse, MD, Ph.D. (17 August 1999). The document was not admitted to the proceedings.	
	C223	Opposition to European patent EP-B-0589877, late filed document D66: Crissman & Smith, "Gene-III protein of filamentous phages: evidence for a carboxyl-terminal domain with a role in morphogenesis", Virology 132: 445-455 (1994).	
	C224	Opposition to European patent EP-B-0589877, late filed document D67: Declaration of Dr. Viia Valge-Archer (3 May, 2000)	
	C225	Opposition to European patent EP-B-0589877, late filed document D68: Declaration of Dr. Hiroshi Ueda (3 May, 2000)	
	C226	Opposition to European patent EP-B-0589877, late filed document D69: First Declaration of Dr. Rachel B. Kent (4 February, 2000). The document was objected to by patentees.	
	C227	Opposition to European patent EP-B-0589877, late filed document D71: letter of patentees filed at USPTO on 16 July 1996. The document was objected to by patentees.	
	C228	Opposition to European patent EP-B-0589877, late filed document D72: letter of patentees filed at USPTO on 6 March 1997. The document was objected to by patentees.	
	C229	Opposition to European patent EP-B-0589877, late filed document D73: Opposition by CAT against EP-B-0 564 531 The document was objected to by patentees.	
	C230	Opposition to European patent EP-B-0589877, late filed document D74: Decision of EPOD on EP-B-0 201 184. The document was objected to by patentees.	
	C231	Opposition to European patent EP-B-0589877, late filed document D75: Declaration of Prof. Andreas Plückhun (3 May, 2000). The document was objected to by patentees.	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,622
				Filing Date	March 18, 2004
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	15	of	16	Attorney Docket Number	05569.0004.DVUS11

	C232	Opposition to European patent EP-B-0589877, late filed document D76: Notice of grant awarded to Smith grant application. The document was objected to by patentees.	
	C233	Opposition to European patent EP-B-0589877, late filed document D77: Endemann and Model "Location of filamentous phage minor coat proteins in phage and in infected cells", J. Mol. Biol. 250: 496-506 (1995). The document was objected to by patentees.	
	C234	Opposition to European patent EP-B-0589877, late filed document D79: Extract from MorphoSys website.	
	C235	Opposition to European patent EP-B-0589877, late filed document D80: Written Decision dated 26 May 2000 to revoke EP-B-0436597.	
	C236	Opposition to European patent EP-B-0589877, late filed document D81: 2nd Declaration of Dr. Viia Valge-Archer (31 May, 2000).	
	C237	Complaint filed 4/23/99	
	C238	First Amended Complaint filed 5/6/99	
	C239	Defendant Cambridge Antibody Technology, Limited's Motion to Dismiss plaintiff MorPhosys Ag's Complaint filed 06/8/99	
	C240	Response of Plaintiff MorphoSys Ag to Cambridge Antibody Technology Ltd's First Set of Interrogatories and Request for Production of Documents and Things filed 10/18/99	
	C241	Plaintiff's Supplemental Answer to Interrogatory No. 2	
	C242	Response of Plaintiff-MorphoSys AG to Cambridge Antibody Technology Ltd.'s First Set of Interrogatories and Request for Production of Documents and Things filed 3/27/00	
	C243	Response of Plaintiff MorphoSys AG to Cambridge Antibody Technology Ltd.'s Second set of Interrogatories filed 7/3/00	
	C244	Response of MorphoSys AG to Cambridge Antibody Technology's Third Set of Interrogatories filed 8/14/00	
	C245	Declaration of Edward S. Golub, Ph.D. in Support of Morpho Sys Motion for Partial Summary Judgment of Noninfringement filed 9/1/00	
	C246	Edward S. Golub, Ph.D. Curriculum Vitae	
	C247	Expert Report of Edward S. Golub, Ph.D. dated 6/00 (with Exhibit 1) E. S. Golub Curriculum Vitae-Exhibit 2 E.S. Golub Validity Report and Exhibit 3 Declaration of E.S. Golub regarding Immunological Concepts	
	C248	Rebuttal Expert Report of Edward S. Golub, Ph.D.	
	C249	Reply of Edward S. Golub, Ph.D. to Rebuttal Expert Reports of Edward P. Cohen, M.D. and Ronald H. Jackson, Ph.D. dated 08/01/00	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,622
				Filing Date	March 18, 2004
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	16	of	16	Attorney Docket Number	05569.0004.DVUS11

	C250	Declaration of Carlos F. Barbas III, Ph.D. in Support of MorphoSys Motion for Partial Summary Judgment of Noninfringement filed 9/1/00	
	C251	Carlos F. Barbas III, Ph.D. Curriculum Vitae	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.